Stephen Ezell

Recent policies permitting CMS price setting are hamstringing the U.S. biopharmaceutical industry, as they reduce incentives for pharmaceutical companies to invest in future drug R&D to create life-improving and life-saving medicines.

The Inflation Reduction Act (IRA) undermines innovation in small-molecule drugs by subjecting them to price controls after 9 years, whereas large-molecule drugs (biologics) are allowed 13 years of market pricing. Congress should pass the bipartisan EPIC Act to remedy this issue.

The 1984 Hatch-Waxman Act revolutionized the U.S. pharmaceutical industry, successfully balancing the interests of pharmaceutical innovation and affordability by creating legal pathways for accelerated generic drug competition while extending patent protections and introducing data exclusivities that preserved incentives for novel pharmaceutical innovation.

Trump’s proposed 100 percent tariffs on Taiwanese chips would hike prices, hurt U.S. tech, help China, and alienate a key ally—without bringing jobs home.

The Biden administration's proposed export controls would impose sweeping restrictions on chip exports, risking U.S. competitiveness while failing to effectively address national security concerns.

Reviving U.S. semiconductor manufacturing requires targeted solutions—not broad tariffs that raise costs and hinder global competitiveness.

Again and again, America has pioneered new technologies and then frittered away its leadership—in sectors ranging from semiconductors and solar panels, to televisions and medical devices. We can’t afford to squander another lead in multi-cancer early detection (MCED) because of regulatory roadblocks.

Many of the world’s biggest challenges are health challenges. The good news is that, more than ever, people are meeting these challenges with innovative solutions.

For policymakers to bolster the global competitiveness of their nations and regions, they first must know where they stand. This report benchmarks the 87 regions of India and the United States using 13 commonly available indicators of strength in the knowledge economy, globalization, and innovation capacity.

The scope and magnitude of the trade-off between immediate savings from lower drug prices and future health benefits from clinical development remain poorly understood and quantified. To support rigorous evaluations and inform evidence-based policymaking, it is crucial to invest in this area through research grants and improved access to federal and private data.

There is a need for more rigorous evidence and more recent, high-quality data to inform biopharmaceutical policymaking by shedding light on the relationship between pharmaceutical firms’ expectations of financial returns from new drugs and their ability to invest in further R&D to discover future generations of drugs.

The United States and Japan must make a concerted effort to mutually advance their economic security and counter Chinese economic coercion, while bringing other allied nations aboard the enterprise to the greatest extent possible.

Watch now for an expert panel elucidating the innovation economics of the global semiconductor industry, exploring how the industry is capitalized, and exploring the landscape of global semiconductor competition and policy in the year ahead.

Watch now for a conversation detailing the effect and importance of Manufacturing USA, and emphasizing the importance of sustained investment in the program to policymakers.

Please join the Information Technology and Innovation Foundation for an expert briefing event to discuss the findings of a 20-month ITIF investigation into Chinese firms’ innovative capabilities in key advanced industries, including robotics, chemicals, nuclear power, electric vehicles, semiconductors, AI, quantum computing, and biotechnology.

Stephen Ezell joined an expert panel hosted by The Hill to discuss how nuclear power can help the United States meet unprecedented electricity demand and examine the path ahead after the ADVANCE Act.

Watch now for an expert briefing event on Capitol Hill where panelists discussed an ITIF report exploring Chinese EV innovation, the state of global competition in EVs, China’s aggressive support tactics, and what the United States needs to do to stay competitive.

Stephen Ezell delivers a featured presentation at the 2024 national meeting of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIMBL).

Stephen Ezell presents on the principles of national innovation success to the Colombian think tank INNOS.

Stephen Ezell presents on the state of global geoeconomic competition and avenues for United States-Japan economic security collaboration for the Japan Foundation.

Stephen Ezell presents on the status of the CHIPS and Science Program.

Watch now for an expert panel discussion surrounding the ITIF report examining why the United States lost its lead in other advanced technology industries, and how policymakers can avoid repeating the same mistakes in the biopharmaceutical sector.

Watch now for an expert panel discussion about a new ITIF report that was commissioned to inform the U.S. and Indian governments for their joint initiative on Critical and Emerging Technology (iCET).

Watch now for an ITIF event releasing a report that will explore the Dominican Republic’s preparedness to compete in global semiconductor and PCB value chains.